High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Oscar Health (OSCR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Oscar Health shares rally on a bullish Barclays’ research note. Here’s how high the investment firm believes OSCR stock could fly in 2026.
Oscar Health, Inc. recently amended and restated its employment agreement with co-founder Mario Schlosser as he moved from President of Technology and Chief Technology Officer to Co-Founder & Advisor to the CEO, effective June 1, 2026, while he continues to support the company’s artificial intelligence and digital health agenda and remains on the Board. At the same time, a major Wall Street firm upgraded its view on Oscar Health after Q1 2026 results exceeded expectations and reinforced...
Wells Fargo raises price target on Oscar Health stock to $20. Here’s why the bank turned bullish on OSCR shares.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
